News
Novo aiming for blockbuster sales for FDA-approved semagluti...
Novo Nordisk’s weekly GLP-1 diabetes injection semaglutide has been approved by the US regulator, a potential blockbuster that the firm hopes will allow it to regain market share from Lilly
